MX2021010228A - Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. - Google Patents
Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.Info
- Publication number
- MX2021010228A MX2021010228A MX2021010228A MX2021010228A MX2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A MX 2021010228 A MX2021010228 A MX 2021010228A
- Authority
- MX
- Mexico
- Prior art keywords
- skin cancer
- patient
- inhibitor
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La descripción se refiere a métodos para tratar o inhibir el crecimiento de un tumor en un paciente con cáncer de piel, en donde los métodos incluyen administrar al paciente una cantidad terapéuticamente eficaz de un inhibidor de muerte programada-1 (PD-1) (por ejemplo, un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a PD-1, PD-L1 y/o PD-L2). En determinadas modalidades, el método incluye administrar al paciente una cantidad terapéuticamente eficaz de un inhibidor de PD-1 como tratamiento adyuvante después de que el paciente haya completado la cirugía y, opcionalmente, la radioterapia para cáncer de piel, tal como CSCC, y tenga un alto riesgo de recurrencia de la enfermedad. En determinadas modalidades, el método incluye administrar al paciente con cáncer de piel una cantidad terapéuticamente eficaz de un inhibidor de PD-1 como tratamiento neoadyuvante antes de la cirugía planificada para cáncer de piel. En determinadas modalidades, el método incluye administrar a un paciente con cáncer de piel una cantidad terapéuticamente eficaz de un inhibidor de PD-1 como tratamiento neoadyuvante antes de la cirugía planificada para el cáncer de piel y posteriormente administrar al paciente un inhibidor de PD-1 como terapia adyuvante después de dicha cirugía.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811827P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/020018 WO2020176699A1 (en) | 2019-02-28 | 2020-02-27 | Administration of pd-1 inhibitors for treating skin cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010228A true MX2021010228A (es) | 2021-10-26 |
Family
ID=70057261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010228A MX2021010228A (es) | 2019-02-28 | 2020-02-27 | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220259313A1 (es) |
| EP (1) | EP3930848A1 (es) |
| JP (2) | JP2022521800A (es) |
| KR (1) | KR20210134690A (es) |
| CN (1) | CN113490529A (es) |
| AU (1) | AU2020228296B2 (es) |
| CA (1) | CA3137361A1 (es) |
| IL (1) | IL285050A (es) |
| MA (1) | MA55084A (es) |
| MX (1) | MX2021010228A (es) |
| SG (1) | SG11202108089SA (es) |
| WO (1) | WO2020176699A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| MA44146B1 (fr) | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
| US12516382B2 (en) | 2018-12-07 | 2026-01-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring PD-1/PD-L1 signaling pathway members |
| AU2022219955A1 (en) * | 2021-02-11 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
| WO2024186917A2 (en) * | 2023-03-06 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions for pd-l1 inhibition and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| MX2007013978A (es) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos. |
| CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| KR101562580B1 (ko) | 2007-06-18 | 2015-10-22 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
| BRPI0917592B1 (pt) | 2008-12-09 | 2021-08-17 | Genentech, Inc | Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição |
| BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| JP2015519375A (ja) | 2012-05-31 | 2015-07-09 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｐｄ−ｌ１に結合する抗原結合蛋白質 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016022630A1 (en) | 2014-08-05 | 2016-02-11 | Jiping Zha | Anti-pd-l1 antibodies |
| SG10201913297TA (en) | 2015-03-13 | 2020-02-27 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR102833068B1 (ko) * | 2015-12-17 | 2025-07-14 | 노파르티스 아게 | Pd-1에 대한 항체 분자 및 그의 용도 |
| MA44146B1 (fr) * | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
| PL3439653T3 (pl) | 2016-04-07 | 2021-07-05 | Chemocentryx, Inc. | Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| CN117442719A (zh) | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko active Pending
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/en active Pending
- 2020-02-27 AU AU2020228296A patent/AU2020228296B2/en active Active
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
- 2020-02-27 CA CA3137361A patent/CA3137361A1/en active Pending
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/en not_active Ceased
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
-
2024
- 2024-12-20 JP JP2024225122A patent/JP2025041768A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521800A (ja) | 2022-04-12 |
| KR20210134690A (ko) | 2021-11-10 |
| SG11202108089SA (en) | 2021-08-30 |
| AU2020228296A1 (en) | 2021-10-14 |
| AU2020228296B2 (en) | 2025-10-02 |
| CN113490529A (zh) | 2021-10-08 |
| US20220259313A1 (en) | 2022-08-18 |
| IL285050A (en) | 2021-09-30 |
| JP2025041768A (ja) | 2025-03-26 |
| CA3137361A1 (en) | 2020-09-03 |
| EP3930848A1 (en) | 2022-01-05 |
| MA55084A (fr) | 2022-01-05 |
| WO2020176699A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010228A (es) | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. | |
| CL2021002267A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945) | |
| BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| FI4175951T3 (fi) | Hpk1-estäjiä ja niiden käyttötapoja | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| JP2018502120A5 (es) | ||
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| MX2016015346A (es) | Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| JP2019519499A5 (es) | ||
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| WO2015191568A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer | |
| MX2021010560A (es) | Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer. | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| SG10201609131YA (en) | Zinc-pga compositions and methods for treating cancer | |
| BR112019011350A2 (pt) | terapia de combinação | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| EP4382168A3 (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| MX2022014734A (es) | Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. |